Skip to main content

Second Heart Assist, Inc. Announces Issuance of 20 New U.S. Patent Claims Covering its Circulatory Assist Device Technology Platform

Mission Viejo, California, United States - 03-16-2023 (PR Distribution™) -

March 16th, 2023, Salt Lake City, Utah and Mission Viejo, CA - Second Heart Assist, Inc. has announced that it has obtained patent no. U.S. 11,602,627 on March 14th, 2023 from the US Patent and Trademark Office Titled “Circulatory Assist Pump” with 20 new patent claims. 

This patent further completes Second Heart’s extended IP portfolio across a large family of issued and pending patents.  The Second Heart Assist newly issued patent claims herein includes a true aortic stent based circulatory assist pump with wireless power that maintains pulsatility of both blood flow and aortic wall movement.  This is accomplished while remaining securely fixated (anchored) in place. This unique design is intended to permit durable reliable long duration use without migration or fixation system fractures. 

The patent also includes claims for potential future generation designs including the REGENERATOR TM the first circulatory assist pump intended to provide therapeutic benefit, via controlled bioelectric induced expression of klotho and other proteins, in addition to circulatory assist support >  Klotho is known to be secreted from muscle and kidneys, especially with specific patented bioelectric signals applied, and may have high potential to help revive failing hearts and kidneys as well as for preventing calcification of arteries and heart valves. 

Contrary to the different circulatory assist pumps, the Second Heart Assist technology is designed to remain secure in position above the renal arteries in the aorta without the need for dangerous hooks or barbs. The device beats in pulsations closer to the natural functioning of the cardiovascular system.

The patent includes an issued claim for utilizing harmonic resonance vibrational energy to reduce the risk of blood clotting which has been a long standing Achille's heel in the field of long duration circulatory assist support.  The Second Heart aortic stent based pump features a wide open, high flow through architecture design with rounded elements which has minimal obstructions and stagnation points for blood flow.

Another element of this issued patent is the modular delivery and use of multiple blood movement pumps into the aorta.  Our impellers feature unique curved vane blade elements designed to minimize hemolysis.  This newly issued patent also has a claim which includes further blood flow improvement augmentation with a low hemolysis non-impeller cuffed pulsating stent graft.  This when combined with an impeller based pump in the same aorta can serve to reduce the needed RPMS of the impeller to improve the same amount of flow with less hemolysis. 

Howard J. Leonhardt, Inventor, Co-Founder, Executive Chairman & CEO of Second Heart Assist, Inc. stated “This is a significant milestone for the company and our stakeholders. The receipt of these 20 new issued patent claims by the USPTO reinforces the unique nature of the our multi-generational Second Heart Assist technology platform.”

Jeff Donofrio, President,  adds: “Second Heart Assist is targeting to address great gaps in patient care with a multi-generational product line that is truly unique. Heart failure is the leading cause of hospitalization in the USA for people over 60 costing the U.S. healthcare system greater than $22 billion annually.  We hope to prove through well designed clinical studies that our technology can dramatically reduce heart failure hospital re-admissions and also greatly improve the quality of life of millions of patients.” 

Link to U.S. issued patent is here >

Link to Second Heart Dual Mechanism of Potential Benefit Animation Video > 

About Second Heart Assist, Inc.:   Second Heart Assist, Inc. is focused on the development of a pipeline of next generation circulatory assist devices including for chronic long term use with wireless power.   See 

This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global related markets, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Timelines could be extended even by decades. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.  This news release does not constitute an offer of securities or products for sale in the United States or anywhere else.  We make no claims that the products mention have been proven to be safe or effective.  Patents pending may not be issued.  Patents licensed of issued mentioned may not be maintained for a variety of reasons.  The company lacks sufficient capital to bring these products through all studies and to market and will very likely need to raise more capital or will have to partner with another well financed company to bring these products fully to commercialization. Ability to secure such needed future financing or a future commercial partner must be viewed as a potential high risk of failure. 

Media Contacts:

Company Name: Second Heart Assist, Inc.
Full Name: Howard Leonhardt
Phone: 424-291-2133
Email Address: Send Email

For the original news story, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.